Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report
Abstract:U pper tract urothelial carcinoma (UTUC) is a rare but aggressive malignancy with an incidence of 2 cases per 100 000 people. 1 Cisplatin-based chemotherapy is the standard treatment for advanced UTUC with a very poor prognosis. The median overall survival is 6-15 mo and the 5-y survival rate is <5%. 2 Pembrolizumab, an immune checkpoint inhibitor (ICI), has been introduced for treating advanced urothelial carcinoma (UC) in cisplatin-ineligible patients. 3 However, to our knowledge, there is no report concerni… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.